Home > Boards > US OTC > Miscellaneous >

Oncology Pharma Inc. (ONPH)

ONPH RSS Feed
Add ONPH Price Alert      Hide Sticky   Hide Intro
Moderator: threewheeler, makinezmoney
Search This Board: 
Last Post: 4/6/2020 9:25:13 AM - Followers: 117 - Board type: Free - Posts Today: 1


ONCOLOGY PHARMA Inc.

1 Sansome Street,
Suite 3500
San Francisco, CA
94104
info@oncology-pharma.com
415-869-1036






CURRENT SHARE STRUCTURE


 
 
??
Total shares authorized: 900,000,000 as of date: August 19, 2019


Total shares outstanding: 124,996,092 as of August 19,


Number of shares in the Public Float: 19,927,822 as of date: July 12, 2019










OTCBB : $ONPH







ABOUT
Oncology Pharma Inc. ("ONPH") is a pioneering oncology company dedicated to developing, manufacturing and commercialization of therapeutics. Oncology Pharma  signed a letter of intent (includes a word-wide licence and co-development)  to colloborate with NanoSmart® Pharmaceuticals Inc for its  "novel"  drug delivery vehicle  that can target many types of cancer and other diseases.  One of the keys to NanoSmart's® platform technology is a “patented” (US 7,799,327 and EU 1706145 B1 ), human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. One of the most commonly used anti-cancer drugs (alone and/or in combination with medications) for treating a wide variety of cancers such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is  doxorubicin. A drug such as doxorubicin is “encapsulated”  within a lipid nanoparticle and then coated with NanoSmart’s ANA. The "reformulated"  drug (doxorubicin)  is administered intravenously, traveling in the blood to the tumor site(s). Encapsulating the cancer drug in the nanoparticle helps protect normal, healthy tissues and organs from adverse side effects, while the ANA delivers the loaded nanoparticle directly to necrotic tissue at the tumor site(s). Once anchored there, the nanoparticle slowly releases the cancer drug with an optimal  efficacy and  minimum adverse effects. The results are thus higher anti-tumor efficacy and safer drug delivery. Therapeutic dosing can be optimized and adverse side effects can be further minimized using precision medicine (pharmacogenetics) combined with bioinformatics.   
NanoSmart's® drug delivery platform can be combined synergistically with current therapies or medications, including the Tulynode's patent pending Autologous Immuno-therapy extracorporeal device. 
In addition to the NanoSmart's targeted drug-delivery licence, Oncology Pharma has a "world-wide" licensing agreement with  Tulynode of its "patent pending" Autologous Cellular Immuno-therapy extracorporeal device for a durable therapy response  that can be combined synergistically with current medications including NanoSmart's® drug delivery platform. 
Oncology Pharma prides itself for having a world-class Advisory Board that keeps the Company leadership in the forefront of developing technologies in cancer research and commercialization for  human and veterinary oncology.
Oncology Pharma is committed to its core corporate mission and values of highest U.S. Pharma Code of Conduct standards of behavior for being in compliance with the laws, regulations, company directives and guidance.



 












 


RECENT NEWS

 
Recent News

July 15, 2019

?

Oncology Pharma Appoints Stefan Gruenwald (MD. Ph.D) as an Advisor on its Advisory Board

?

SAN FRANCISCO, CA, July 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma, Inc.  (OTCPK: ONPH) is pleased and honored to announce the appointment of Stefan Gruenwald (MD. Ph.D) to its Advisory Board.  Dr. S. Gruenwald brings more than 30 years of experience and vast knowledge in both the clinical, scientific and business fields to the company.  His contribution to meeting the vision, mission and goals are a great asset to the company. Dr. Gruenwald has had an impressive career as the former VP of R&D at Becton Dickenson, the former CSO at Pharmingen and the former President at Orbigen. He is currently a co founder and president of Diagnomics.  

"I am delighted to join a young and dynamic company like Oncology Pharma and I hope to be able to make significant contributions to its profitable growth," said Dr. Gruenwald. "I am honored to be part of an exciting management team and I believe that this company has a bright future."

 

In addition, Oncology Pharma is pleased to announce its new website: www.oncology-pharma.com.   

 

About Oncology Pharma, Inc.

ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the “Company”) is a pioneering oncology company dedicated to developing, manufacturing, and commercializing therapeutics. The Company has licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. The Company is currently engaging in research and development of therapeutics for oncology, and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.

 

Forward-looking Statements

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.

 

Contacts:

For additional Information, please contact at: 

One Sansome Street, Suite 3500 

San Francisco, CA 94104 

Phone: 415-869-1038 Fax: 415-946-8801 

Email: info@oncology-pharma.com  

Website: www.oncology-pharma.com  

March 25, 2019

 

SourcingLink.net Signs a Letter of Intent with NanoSmart Pharmaceuticals, Inc. for a Licensee and Co-Development Collaboration of NanoSmart's Proprietary Targeted Drug Delivery System for Cancer Drugs

?

SourcingLink.net, an early stage oncology company, is a pioneering company based in San Francisco, California, USA. The company announced today that it signed a Letter of Intent to collaborate with NanoSmart Pharmaceuticals, Inc., a California-based company developing novel drug formulations to treat cancer. The collaboration includes co-development and an exclusive, world-wide license for specific formulations to treat cancer utilizing NanoSmart's proprietary ‘targeted’ drug delivery system that is designed to enhance delivery of drugs to a wide variety of cancer tumors. 

 

SourcingLink.net is excited about the collaboration opportunity because new or already-approved chemotherapy drugs can be reformulated with greater efficacy and safety for treating cancer patients. The company believes that the reformulated drugs, subject to approval by the FDA and/or regional regulatory bodies, may be used as a monotherapy, or as a ‘combo-therapy’ with SNET’s autologous cellular immuno-therapy approach, or with other therapies such as immune check point inhibitors. SNET expects to enter into a full exclusive ‘world-wide’ licensing and co-development agreement with NanoSmart under the terms of the Letter of Intent signed on February 25th, 2019.

 

The use of NanoSmart's enhanced drug delivery platform combined with pharmacogenomics and liquid biopsy for personalizing the therapy should augment cancer drug effectiveness and safety, and improve treatment monitoring, according to the company. Currently, SNET is focused on developing its ‘core’ autologous extracorporeal immuno-therapy device for a durable response.

 

About SourcingLink.net

SourcingLink.net, Inc. ("SNET") is a pioneering  oncology company dedicated to developing , manufacturing and  commercialization of therapeutics. SNET licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device.  SourcingLink.net prides itself for having a world-class Advisory Board that keeps the Company leadership in the forefront of developing technologies in cancer research, biotechnology and healthcare. SourcingLink.net is currently engaging in research and development of therapeutics for oncology. SourcingLink.net is committed to its core corporate mission and values of highest U.S. Pharma Code of Conduct standards of behavior for being in compliance with the laws, regulations, company directives and guidance.

About NanoSmart Pharmaceuticals, Inc.

NanoSmart® Pharmaceuticals is a privately-held California corporation that is developing nanoparticle drug delivery platforms that utilize anti-nuclear antibody (ANA) to target existing drug therapies to areas of necrosis present in virtually all solid cancer tumors.

Forward-looking Statements: 

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements, which contain words such as "expect", "believe" or "plan", by their nature address matters that are, to different degrees, uncertain.  These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements.  We do not undertake to update our forward-looking statements.

 

For additional Information, please contact at:

One Sansome Street, Suite 3500

San Francisco, CA 94104

Phone: 415-869-1038  

Fax: 415-946-8801

email: info@sourcinglink.net

website: www.sourcinglink.net

February 26, 2019

?

SourcingLink.net Signs a Letter of Intent with NanoSmart Pharmaceuticals, Inc. for a Licensee and Co-Development Collaboration of NanoSmart's Proprietary Targeted Drug Delivery System for Cancer Drugs

 

 

 

SourcingLink.net, an early stage oncology company, is a pioneering company based in San Francisco, California, USA. The company announced today that it signed a Letter of Intent to collaborate with NanoSmart Pharmaceuticals, Inc., a California-based company developing novel drug formulations to treat cancer. The collaboration includes co-development and an exclusive, world-wide license for specific formulations to treat cancer utilizing NanoSmart's proprietary ‘targeted’ drug delivery system that is designed to enhance delivery of drugs to a wide variety of cancer tumors. 

 

SourcingLink.net is excited about the collaboration opportunity because new or already-approved chemotherapy drugs can be reformulated with greater efficacy and safety for treating cancer patients. The company believes that the reformulated drugs, subject to approval by the FDA and/or regional regulatory bodies, may be used as a monotherapy, or as a ‘combo-therapy’ with SNET’s autologous cellular immuno-therapy approach, or with other therapies such as immune check point inhibitors. SNET expects to enter into a full exclusive ‘world-wide’ licensing and co-development agreement with NanoSmart under the terms of the Letter of Intent signed on February 25th, 2019.

 

The use of NanoSmart's enhanced drug delivery platform combined with pharmacogenomics and liquid biopsy for personalizing the therapy should augment cancer drug effectiveness and safety, and improve treatment monitoring, according to the company. Currently, SNET is focused on developing its ‘core’ autologous extracorporeal immuno-therapy device for a durable response.

 

Forward-looking Statements:

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as "expect", "believe" or "plan", by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

 

 

One Sansome Street, Suite 3500

San Francisco, CA 94104

Phone: 415-869-1038  

Fax: 415-946-8801

email: info@sourcinglink.net

website: www.sourcinglink.net

February 12, 2019

?

SourcingLink.net to Investigate the Potential of Combining its Novel Autologous Immune-Therapy with Synergistic Oncology Therapies

 

San Francisco, CA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SourcingLink.net (OTC PINK: SNET), based in San Francisco, is a pioneering biotech company focused on oncology .  The company is developing its proprietary autologous immune-therapy approach in oncology.  SNET envisions developing its strategic goals for the most effective therapies with a durable response and minimum adverse effects.  The company believes that its autologous immune-therapy as a monotherapy and/or when combined with other therapies such as chemos, Immune Check Point Inhibitors, radiation and /or immuno-therapies will be a "game changer". 

The National Cancer Institute in 2018 estimated 1,736,350 new cases of cancer in the US and 609,640 people died as a result of cancer.  According to a 2018 report by WHO, cancer is the second leading cause of death in the world.  Cancer, according to the report was responsible for an estimated 9.6 million deaths in 2018. The global growth in oncology drug market according to the IMS is expected to be between 7.5-10.5% through 2020 and the market is projected to reach $150 billion.  Subject to regulatory approval, SourcingLink.net expects to capture the market share through commercialization of its products and/or through strategic partnerships with the big pharmas.

SourcingLink.net has licensed and strategically partnered with pioneering biotech and pharmaceutical companies in the rapidly emerging field of oncology for achieving its mission, goals and vision.

About SourcingLink.net:
SourcingLink.net, Inc. ("SNET") is a pioneering  oncology company dedicated to developing , manufacturing and  commercialization of therapeutics. SNET licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device.  SourcingLink.net prides itself for having a world-class Advisory Board that keeps the Company leadership in the forefront of developing technologies in cancer research, biotechnology and healthcare. SourcingLink.net is currently engaging in research and development of therapeutics for oncology. SourcingLink.net is committed to its core corporate mission and values of highest U.S. Pharma Code of Conduct standards of behavior for being in compliance with the laws, regulations, company directives and guidance.

Forward-looking Statements: 

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements, which contain words such as “expect”, “believe” or “plan”, by their nature address matters that are, to different degrees, uncertain.  These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements.  We do not undertake to update our forward-looking statements.

 

One Sansome Street, Suite 3500

San Francisco, CA 94104

Phone: 415-869-1038  

Fax: 415-946-8801

email: info@sourcinglink.net

website: www.sourcinglink.net

February 5, 2019

?

SourcingLink.net to Leverage Pharmacogenomics in Its Oncology Therapy Development and Clinical Trial Program

 

San Francisco, CA, Feb. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SourcingLink.net (OTC PINK: SNET) is announcing that it will harness the power of pharmacogenomics in its oncology therapy development and clinical trials.  Pharmacogenomics studies how the genome influence response to a drug.  Dr. Mahant, a SAB member, stated that pharmacogenomics is a "powerful tool" in drug development and clinical trials because pharmacogenomics will allow drug target identification, patient stratification, it will reduce adverse side effects, allow optimal dosing, it will reduce the cost and drug development time, the data will help in any requirements for regulatory submissions and labeling of the drug, and, of course, it will help to "personalize" the drug therapy.

About SourcingLink.net:

SourcingLink.net, Inc. ("SNET") is a pioneering  oncology company dedicated to developing , manufacturing and  commercialization of therapeutics. SNET licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device.  SourcingLink.net prides itself for having a world-class Advisory Board that keeps the Company leadership in the forefront of developing technologies in cancer research, biotechnology and healthcare. SourcingLink.net is currently engaging in research and development of therapeutics for oncology. SourcingLink.net is committed to its core corporate mission and values of highest U.S. Pharma Code of Conduct standards of behavior for being in compliance with the laws, regulations, company directives and guidance.

Forward-looking Statements: 

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements, which contain words such as “expect”, “believe” or “plan”, by their nature address matters that are, to different degrees, uncertain.  These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements.  We do not undertake to update our forward-looking statements.

 

One Sansome Street, Suite 3500

San Francisco, CA 94104

Phone: 415-869-1038  

Fax: 415-946-8801

email: info@sourcinglink.net

website: www.sourcinglink.net

August 19, 2019

?

Update: Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide License and Co-Development of Its Broad-Spectrum Anti-Cancer Drug, KTH 222

?

SAN FRANCISCO, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH)is pleased to announce that it signed a Letter of Intent with Kalos Therapeutics (Phoenix, AZ) for a world-wide license and co-development of Kalos's lead anti-cancer drug, KTH 222. The expected license and co-development of KTH 222 as a monotherapy and/or in combination with NanoSmart's ANA-conjugated liposomal doxorubicin targeted delivery is licensed exclusively worldwide by Oncology Pharma. Doxorubicin is one of the most commonly used chemotherapies for treating a wide variety of cancers such as breast, ovarian, lung, bladder, lymphoma, and Kaposi's sarcoma. The KTH 222 combined with the NanoSmart's targeted delivery of doxorubicin provides an excellent synergy between the two therapies while offsetting further the potential cardiotoxicity inherent with doxorubicin.   

?

Kalos Therapeuticsis developing a platform of drugs containing multiple array of natriuretic peptide which have demonstrated a broad spectrum of anti-tumor activity with negligible or no known adverse effects. In a Pre-IND Study using the parent drug involving a total of eighty-eight patients, including 22 healthy patients, the study demonstrated safety and therapeutic efficacy. Kalos's leading drug candidate, KTH 222, regulates cell growth via inhibition of the mitogen-activated protein kinase (MAPK) pathway. Kalos is looking to change the care paradigm for treating cancer patients as KTH 222 can be a lead therapy, or used in combination with existing therapies to improve efficacy and reduce toxicity, and mitigate resistance or reverse it. There are nearly 17 million patients living with a cancer diagnosis without a safe nontoxic maintenance therapy; Kalos believes it will attain this lofty goal and become the Holy Grail for “cancer tune up,” and a therapeutic option to a drug Holiday.

?

About Kalos Therapeutics

Kalos is pursuing a multiphase strategy to reorient today’s therapeutic approach to cancer patients while driving changes to transform therapeutic approaches for unmet and rare medical conditions. Kalos has a lead compound KTH 222 which is more promising than “standard of care” drugs with difficult to treat tumors. Kalos[gc1]  Therapeutics, Inc. CEO, George Colberg, announced, “The collaboration with the Oncology Pharma has provided new opportunities for Kalos to advance its drug development program changing how cancer patients can be treated with safer, nontoxic approaches improving the patient’s quality of life. The possibility of bringing to market a safer more promising version of the Oncology Pharma product line is extremely exciting!”

?

Kalos is devoted to treating the unmet needs of people living with incurable diseases, while doing so with less toxic and debilitating side effects commonly associated with chemotherapies. Kalos believes that by leveraging nature and all of the body’s mechanisms, they have created new, safer approaches to cancer and diseases that affect the eye as well.  Kalos has several applications for animal health based on both its 8 amino acid and a 15 amino acid drug KTV-111. Kalos aims to treat dangerous and debilitating diseases and improve the quality of life for the patient and their families.

?

ABOUT ONCOLOGY PHARMA, INC.

ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") is a pioneering oncology company dedicated to developing, manufacturing, and commercializing therapeutics. The Company has licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. The Company is currently engaging in research and development of therapeutics for oncology, and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.

?

FORWARD LOOKING STATEMENTS

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the  obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.

CONTACTS:

For additional Information, please contact the Oncology Pharma at:

One Sansome Street, Suite 3500

San Francisco, CA 94104

Phone: 415-869-1038 Fax: 415-946-8801 

Website: email: info@oncology-pharma.com 

 
 
 
 
ONPH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
News News Alert: Oncology Pharma, Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID- 04/06/2020 08:20:53 AM
PostSubject
#9561  Sticky Note SAN FRANCISCO, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) threewheeler 12/31/19 02:41:45 PM
#9587   ONPH...0175...SAN FRANCISCO, CA, April 06, 2020 (GLOBE NEWSWIRE) georgie18 04/06/20 09:25:13 AM
#9586   ONPH over 500k on bid, looking like someone threewheeler 03/04/20 12:07:35 PM
#9585   Niice. Chart looks like another pop may jjr04001 03/04/20 07:20:45 AM
#9584   OTC Markets back to Current https://www.otcmarkets.com/market-activity/corporate threewheeler 03/04/20 02:39:26 AM
#9583   move coming? jjr04001 03/03/20 07:07:28 AM
#9582   if u sold Id put some bids in threewheeler 02/13/20 01:12:27 PM
#9581   only have a handful here not worth selling threewheeler 02/13/20 12:39:54 PM
#9580   Any idea? I just saw most of my JMMatthews 02/13/20 12:37:58 PM
#9579   ONPH following SPOM wonder whats up here threewheeler 02/13/20 12:35:43 PM
#9578   $ONPH : Here she goes.............. taking $0.059 makinezmoney 02/13/20 12:33:36 PM
#9577   Holy smokes getting nutty now. News leak? JMMatthews 02/13/20 12:33:33 PM
#9576   yeap got a small handful here to keep threewheeler 02/06/20 01:16:20 PM
#9575   $ONPH: Cheapest Oncology immunotherapy play out there makinezmoney 02/06/20 12:48:09 PM
#9574   Oncology Pharma, Inc. Narrows Focus on Funding Efforts threewheeler 01/28/20 10:54:14 AM
#9573   Volume sporadic here but moves easy. Could be JMMatthews 01/07/20 10:36:55 AM
#9572   $ONPH fighting CANCER let’s gooo$$$$$! slickinvest 01/02/20 08:28:46 AM
#9571   Good morning ONPH!! PennyStock Alert 01/02/20 07:58:02 AM
#9570   ONPH SECURITY DETAILS threewheeler 01/02/20 05:35:49 AM
#9569   I just typed in the wrong symbol Snug Harbour 01/02/20 04:54:32 AM
#9568   Well that's how i know this slump pump Sillywillie 01/02/20 04:44:17 AM
#9567   Never heard of this 5 minutes ago and Snug Harbour 01/02/20 04:29:09 AM
#9566   I just want To see what this companies Sillywillie 01/02/20 04:27:16 AM
#9565   Do you like anything? I don't own it Snug Harbour 01/02/20 04:07:10 AM
#9564   What does this company even do? What is Sillywillie 01/02/20 03:50:49 AM
#9563   ONPH most shares issued above current tax selling threewheeler 12/31/19 03:06:30 PM
#9562   ONPH SECURITY DETAILS threewheeler 12/31/19 02:42:26 PM
#9561   SAN FRANCISCO, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) threewheeler 12/31/19 02:41:45 PM
#9560   ONPH grabbed a handful here today, huge financing threewheeler 12/31/19 02:40:14 PM
#9559   Grabbed those 3's puffadder 12/23/19 10:42:10 AM
#9558   Awesome news $$ slickinvest 12/23/19 10:38:08 AM
#9557   We shall see... georgie18 12/23/19 10:16:36 AM
#9556   This is getting very real $$$ slickinvest 12/23/19 10:15:06 AM
#9555   ONPH...033...Psar flipped to a Bullish Buy Position...off the georgie18 12/23/19 09:47:05 AM
#9554   https://www.globenewswire.com/news-release/2019/12/23/1964006/0/en/Oncology-Phar JMMatthews 12/23/19 09:08:44 AM
#9553   ONPH...0201...https://www.otcmarkets.com/stock/ONPH/news/Oncology-Pharma-Receives-LOI-for-Financing- georgie18 12/23/19 08:38:29 AM
#9552   ONPH...0151...Back in on the Oversold dip...Last move was georgie18 12/18/19 01:18:37 PM
#9551   $ONPH: Oncology space is hot... $THOR takeover yesterday makinezmoney 12/10/19 09:45:23 AM
#9550   03/2019 CONNECT2MED PLATFORM PILOT PRGM Dick Goblair 11/13/19 12:42:50 PM
#9549   https://www.financialbuzz.com/breaking-news-oncology-pharma-and-ribera-solutions JMMatthews 11/06/19 09:35:52 AM
#9548   ONPH...0389...https://www.otcmarkets.com/stock/ONPH/news/Oncology-Pharma-and-Rib georgie18 11/06/19 08:54:08 AM
#9547   I have been looking and cant find anything GM5 11/01/19 10:21:02 AM
#9546   $ONPH: Amgen bought stake in Beigene yesterday... ONCOLOGY !!!!!!!!! makinezmoney 11/01/19 09:12:27 AM
#9545   https://www.otcmarkets.com/stock/ONPH/security ONPH $$$ JMMatthews 10/22/19 01:26:46 PM
#9544   When you find a stock that only goes georgie18 10/21/19 09:30:17 AM
#9543   A red close.....I'm done with it time to sell GM5 10/15/19 04:02:25 PM
#9542   This is crap, back down it goes. GM5 10/15/19 11:05:34 AM
#9541   ONPH...06...Hod... georgie18 10/15/19 10:16:32 AM
#9540   Great News! They keep adding quality people GM5 10/15/19 10:03:39 AM
#9539   https://www.biospace.com/article/releases/oncology-pharma-appoints-dr-vijay-maha JMMatthews 10/15/19 09:29:55 AM
#9538   duh MMs pay attention closely. you can tell a Dick Goblair 10/10/19 09:15:51 PM
PostSubject